BEAM: Multiplikator P/S Beam Therapeutics Corp
Beam Therapeutics Inc. (BEAM) focuses on an innovative DNA base editing platform, diversifying risks across oncology and hematology. This P/S chart visualizes this market valuation, where the metric level stands at 16.10. The company develops one-time treatments for severe pathologies, attracting major partners. Simultaneously, the business is expanding its development portfolio for liver and blood disease therapies.
Beam Therapeutics Corp (BEAM) - rincian metrik lan laporan keuangan
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Beam Therapeutics Inc.|BEAM - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Beam Therapeutics Inc.|BEAM - Gunggung utang perusahaan|Utang-utang marang aset resik Beam Tx|BEAM - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Beam Therapeutics|Koefisien jangkoan perantara beamtx.com
- indikator bathi lan kelipatan valuasi:
BEAM - Penghasilan resik|Penghasilan resik sing dikarepake Beam Therapeutics Inc.|BEAM - Pangali P/E|Kapitalisasi marang proyeksi bathi Beam Tx|BEAM - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Beam Tx|BEAM - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Beam Therapeutics|BEAM - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan beamtx.com|BEAM - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Beam Therapeutics Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:BEAM, Beam Therapeutics
The P/S multiple relates market capitalization to annual sales volume, measuring the premium the market is willing to pay per unit of revenue in anticipation of future growth. For Beam Therapeutics Inc. (BEAM), whose profitability remains hypothetical due to high clinical trial costs, the current price-to-sales ratio serves as an indicator of speculative expectations, allowing for an assessment of the premium paid for high-risk developments.
Perusahaan pesaing
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Sarepta Corp|Rasio rega marang pendapatan Twist Bioscience, Inc. (TWST)|Kapitalisasi marang pendapatan 10x Genomics TXG|Rasio rega marang pendapatan Intellia Therapeutics NTLA|Kapitalisasi marang volume dodolan STOK (Stoke Therapeutics, Inc.)|BLFS - Rasio rega marang pendapatan|Rega marang dodolan Wave Pharma|mazetx.com (MAZE) - Rasio rega marang pendapatan|SION - Koefisien rega marang pendapatan|PRME (Prime Medicine Inc) - Multiplikator P/S|Taysha Gene Therapies, Inc. - Rasio rega marang dodolan|Multiplikator P/S QURE|MGTX: Rasio rega marang dodolan|Rasio rega marang pendapatan REGENXBIO RGNX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
